DOCSLIB.ORG

Profile Uses and Administration Adverse Effects and Precautions

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Profile Uses and Administration Adverse Effects and Precautions 618 Antihistamines 2. Paton DM, Webster DR. Clinical pharmacokinetics of H1-receptor Uses and Administration antagonists (the antihistamines). Clin Pharmacokinet 1985; 10: 477-97. Brompheniramine maleate, an alkylamine derivative, is a sedating antihistamine with antimuscarinic and moderate Preparations .......... ... .. ......... sedative actions. ProprietaryPreparations (details are given in Volume B) Brompheniramine is a racemic mixture; dexbromphe­ niramine, the dextrorotatory isomer, has about twice the Single-ingredient Preparations. Fr.: Dimegan; Gr.: Dimetane; activity of brompheniramine by weight. Brompheniramine Hong Kong: Bromitont; Malaysia: Bomex; Singapore: Bomex; maleate and dexbrompheniramine maleate are used for the Thai.: Babycoldt; Bomine; Bromma; Bromphen; Bromsin; symptomatic relief of allergic conditions, mainly rhinitis Dimetanet; Probrom; USA: Alahist IR; Bidhistt; J-Tan; Lodrane (p. 612.1) and conjunctivitis (p. 611.1). They are common 12t; Lodrane 24t; Oraminic II; P-Text. Pharmacopoeias. In US. ingredients of compound preparations for the symptomatic Multi-ingredient Preparations. Arg.: Factus; Austral.: Dirnetapp 611.2). USP 36: (Bromodiphenhydramine Hydrochloride). A white treatment of coughs and the common cold (p. DM; Dimetapp; Braz.: Bialerge; Decongex Plus; Dimetapp; to pale buff-coloured, crystalline powder having no more Bromphenirarnine tannate has been used similarly. Winter AP; Canad.: Cold And Allergy Liquidt; Cold Syrup; Brompheniramine maleate than a faint odour. Soluble in less than of water, in 2 of is given in usual oral doses of Dimetane Expectorant C; Dimetane Expectorant DC; Dimetapp alcohol and of chloroform, I in 3500 of ether,I and 1 Iin 31 of 4 mg every four to six hours. It has also been given by Chewables for Kids; Dirnetapp Coldt; Dimetapp DM Cough & Cold; Dimetapp·C; Dimetapp; DM Cough and Cold; Drixoral isopropyl alcohol; insolubleI in petroleum spirit. Store in subcutaneous, intramuscular, or slow intravenous injec­ Day/Nightt; Drixoral; Drixtabt; Extra Strength Cold Syrup: airtight containers. tion. Dexbrompheniramine maleate is normally given as an Extra Strength DM Cough and Cold; Oral Infant Cold Dropst; (�'i'); (il'PTJl!t); (!J;Pf'l(); ingredient of decongestant preparations containing pseudo­ China: Coleta! Neosed Rhinobol Cz. : Profile ephedrine. The dose of dexbrompheniramine maleate in Disophrol; Gr.: Dimetapp New; Dimetapp; Disofrin; Hong Kong: Arnericat; B.P.P.t; BPP Cough Syrupt; Brorn-PP; Brom­ these oral combinations is 6 mg no more than twice daily. Bromazine hydrochloride, a monoethanolamine derivative, Ramine Compound; Bromphenext; DF Multi-Symptomt; Modified-release oral preparations of brompheniramine is a sedating antihistamine (p. 610.1) with antimuscarinic Dimeta-2; Dimetapp; Drixoralt; Eascold; Eurotapp; Fastolint; and marked sedative actions. It has been used in maleate or dexbrompheniramine maleate are available in Fludanet; Futalint; Futarat; Mecostopt; Unihist; Vidatapp combination preparations for the symptomatic treatment some countries; dosage is specific to a particular Fortet; Vidatappt; Indon.: Alco Plus DMP; Alco Plus; Drixoral; of coughs and the common cold. formulation. Irl. : Dimotane Cot; Tlvico; Malaysia: Rinafort; Unihist; Mex.: For dosage in children, see below. Afrinext; Cripofen; Dimetapp; Sedalmerck Flu; NZ: Dimetapp DM Cold & Cough; Dimetapp; Philipp.: Bromitapp; Dimerrin; Administration in children. Brompheniramine maleate Dimetapp; DMT; Hisdec; Nasatapp; Nosterot; Pediatapp; Pen­ ProprietaryPreparations (details are given in Volume B) may be given orally to children, for the symptomatic relief brosol; PPB; Remedril; Rhinodec; Rhinotapp; Snizee; Solvamin; of allergic conditions such as rhinitis and conjunctivitis; Zeditapp; Pol.: Disophrolt; NeoAfrin; Port.: Constipalt; Ilvico Multi-ingredient Preparations. USA: Ambenyl Cough Syrupt; doses are as follows: N; S.Afr. : Dimetappt; Ilvicot; Singapore: Dimetapp; Rinafort; Amgenal Caught; Bromotuss with Codeinet. • children aged 2 to 6 years: mg every four to six hours Spain: Disofrol; Ilvico; Swed.: Disofrolt; Switz.: Disofrolt; Aorinyl; Asiatapp; Bepeno-G; Bepeno; Bluco; Broma� • those aged 6 to 12 years: 2 mgI every four to six hours Thai.: PharmacopoeialPreparations those aged over 12 years: 4 mg every four to six hours vont; Bromceryl; Bromesep Elixir; Bromesep Expectorant; Bro­ USP 36: Bromodiphenhydramine Hydrochloride and Codeine • Bromphenirarnine maleate is a common ingredient of mesep Syrup; Bromiphed; Bromlamine; Bromped; Bromsuno; Phosphate Oral Solution; Bromodiphenhydramine Hydro­ compound preparations for the symptomatic treatment of Bromtussia DCt; Bromtussia; Brontus; Centapp; Chintacold; chloride Elixir. Cold-tab; Coldate; Cotapp Expectorant; Cotapp; Daminate; coughs and the common cold. However, such preparations Decon; Dimetapp; Ditap; Leffrin; Meditapp Expectorantt; Medi­ should be used with caution in children, and generally tapp; MEXY; Minra; Nartap; Nased; Nasorest Expectorant; 614.1. avoided in young children, for details see p. Nasorest; Nasotane; Nasotapp; Pharcold; Pharfed; Phemine; Brompheniramine Maleate Polamine; Polydine; Polydrop; Postap Expectorantt; Postapt; (BANM, r/NNM) Adverse Effects and Precautions Rhinadinet; Sinufen; St Luke's Cold; Topamine; Unihist; Turk.: · Disophrol; UK: Dimotane Co; Dimotane Expectorant; USA: 12 As for the sedating antihistamines in general, p. 613.1 and !lromfeniramin Male'lt: Bromf�nirarnina,.. ·· miJI�at; Hour Antihistamine Nasal Decongestant; 12 Hour Cold; Accuh­ de! 613.3, 8(6mfeqirim1in,maleat; Bromfen.lramil'lm�lea):;•. f1rornf�nira· p. respectively. ist DM Pediatric; Accuhist PDXt; Alacol DMt; Alahist DM; o mlrrma!<li.nat; .. B f iramin . mal�at : . .Bto!Ji ife olramiini" Allent; Anaplex DM; Anaplex HDt; B-Vex PD; Balacall DM; BP n Breast feeding. The American Academy of Pediatrics1 ma�qa;ti; Bromphenirarnine;rorn e Maleate as New Allergy DMt; BPM PE DM; Brofed; Brohist D; Brom/PE/ �e; · Sromph;;niramini states that, although usually compatible with breast feed­ M<!leas; 8rompl\eqirami!)tni)iE:at;. Maleato de btqmf�nirarnic DM; Bromadine-DM; Bromaline DMt; Bromalinet; Bromarest ing, preparations used by breast-feeding mothers which DX; Bromatan-DMt; Bromatane DX; Bromdex D; Bromfed­ r:ta: Para�o!Jid)tlamine N\al�<.lte: . 5PoM¢'ef:IV1Pa��Ha , contain dexbrompheniramine maleate with pseudoephe· DM; Bromfed-PD; Bromfed; Bromhist PDXt; Bromhist PDX; Man;;<�tr (±:)'c3,(4·Bromqpher;yl)-NN-�imethyl;3·(2-py�id)tl)p qpyl!l' drine have resulted in crying, irritability, and poor sleep Bromhist-DMt; Bromhist-NRt; Bromhistt; Bromphen DX . ·. · ·· • · · ·· min<;> maleate, .•.. · · · · • hydrpgen . •. • ···· patterns in the infant. Cough; Brompheniramine Cough; Brompheniramine/Pseudo­ . · .. • ..•.•.· . ·•.• C16H,,BrN2,C.,H"0,1=435.3 . > . < 1. American Academy of Pediatrics. The transfer of drugs and other ephedrine DM; Brotapp DM; Brotapp; Brovex ADTt; BroveX LAS ,..,_. < chemicals into human milk. Pediatrics 2001; 108: 776-89. [Retired May CBt; BroveX CBXt; BroveX PB Ct: BroveX PB CXt; BroveX 86-22-6 (o romphenirqmine); 98()- 11-2 (bromphenir­ 2010] Correction. ibid.; 1029. Also available at: http://aappolicy. PB DMt; Brovex PBt; Brovex PDt; Brovex PEB DM; BroveX · aappublications. org/cgi content/full/ pediatrics% 3 b l 0 8/3/776 (accessed Arc BOJ I PEB; BroveX PSB DM; BroveX PSB; BroveX PSE DM; BroveX amirle:..,. maleaROtSAte}. •. 08104104) l<TC V<:f ·......:··Of?(k5AB61. PSE; C-Tan Dt; Carbodex DM; Cenhist; Childrens Dimaphen DM Cold & Cough; Coldec DM; Comtrex Acute Head Cold; Effects on the blood. Agranulocytosis in a 34-year-old Conex Cold & Allergyt; CPB WC; Cytuss-HC NRt; Dallergy Ut<l/r-:- IXA 7C9ZN03. alcoholic man was possibly associated with bromphenir­ Pharmacopoeias. In Eur. DMt; DEKA; Dexaphen-SA; Dicel CD; Dimetane DXt; Dime­ amine therapy. 1 tapp Childrens Cough & Cold; Dimetapp Cold & Fever; Dime­ Ph. Eur. 8: (Brompheniramine Maleate). A white or almost I. Hardin AS, Padilla F. Agranulocytosis during therapy with a tapp DM; Dimetapp Nighttime Flu; Dimetapp; Disobrom; Diso­ white, crystalline powder. Soluble in water; freely soluble in brompheniramine-medication. 1 Arkansas Med Soc 1978; 75: 206-8. phrol; DM/PSE/BPM; Dristan Allergy; Dristan Cold Maximum alcohol, in dichloromethane, and in methyl alcohol. A 1% Strength Multi-symptom Formula; Drixoral Cold & Allergy; solution in water has a pH of 4.0 to 5.0. Protect from light. Extrapyramidal disorders. Facial dyskinesias have been Drixoral Cold & Flu; Drixoral Plus; Drixoral; Drocon-CS; Enda­ USP 36: (Brompheniramine Maleate). A white, odourless, reportedu after use of antihistamines including brom­ Cof-AC; EndaCof·DHt; Endafed; Histacol DMt; Histussin HC; crystalline powder. Soluble in 5 of water, 1 in 15 of alcohol phenirarnine or dexbrompheniramine maleate. lofed; J-COF DHC; J-Tan D Hct; J-Tan Dt; Lodrane 12D; and of chloroform; slightly solubleI in ether and in benzene. I. Thach BT, et at. Oral facial dyskinesia associated with prolonged use of Lodrane D; Lodranet; LoHist PEB DM; LoHist PEB; LoHist PSB; antihistaminic decongestants. N Eng! 1 Med 1975; 293: 486-7 pH of a 1% solution in water is between 4.0 and 5.0. Store in LoHist-DM; M-End Max D; M·End PE; M-END WC; Mar-Co! (brompheniramine maleate, chlorpheniramine maleate, and phenind­ airtight containers. Protect from light. BP; Maximum Strength Dristan Cold; Mesehist WC; Myphe­ amine tartrate). tane DXt; Nalex AC; Neo DM; P-Hist DM; Panatuss DXP; PBM 2. Barone DA, Raniolo J. Facial dyskinesia
Load more

Recommended publications
  • Guidelines for the Forensic Analysis of Drugs Facilitating Sexual Assault and Other Criminal Acts
    Vienna International Centre, PO Box 500, 1400 Vienna, Austria Tel.: (+43-1) 26060-0, Fax: (+43-1) 26060-5866, www.unodc.org Guidelines for the Forensic analysis of drugs facilitating sexual assault and other criminal acts United Nations publication Printed in Austria ST/NAR/45 *1186331*V.11-86331—December 2011 —300 Photo credits: UNODC Photo Library, iStock.com/Abel Mitja Varela Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Guidelines for the forensic analysis of drugs facilitating sexual assault and other criminal acts UNITED NATIONS New York, 2011 ST/NAR/45 © United Nations, December 2011. All rights reserved. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. List of abbreviations . v Acknowledgements .......................................... vii 1. Introduction............................................. 1 1.1. Background ........................................ 1 1.2. Purpose and scope of the manual ...................... 2 2. Investigative and analytical challenges ....................... 5 3 Evidence collection ...................................... 9 3.1. Evidence collection kits .............................. 9 3.2. Sample transfer and storage........................... 10 3.3. Biological samples and sampling ...................... 11 3.4. Other samples ...................................... 12 4. Analytical considerations .................................. 13 4.1. Substances encountered in DFSA and other DFC cases .... 13 4.2. Procedures and analytical strategy...................... 14 4.3. Analytical methodology .............................. 15 4.4.
    [Show full text]
  • MSM Cross Reference Antihistamine Decongestant 20100701 Final Posted
    MISSISSIPPI DIVISION OF MEDICAID Antihistamine/Decongestant Product and Active Ingredient Cross-Reference List The agents listed below are the antihistamine/decongestant drug products listed in the Mississippi Medicaid Preferred Drug List (PDL). This is a cross-reference between the drug product name and its active ingredients to reference the antihistamine/decongestant portion of the PDL. For more information concerning the PDL, including non- preferred agents, the OTC formulary, and other specifics, please visit our website at www.medicaid.ms.gov. List Effective 07/16/10 Therapeutic Class Active Ingredients Preferred Non-Preferred ANTIHISTAMINES - 1ST GENERATION BROMPHENIRAMINE MALEATE BPM BROMAX BROMPHENIRAMINE MALEATE J-TAN PD BROMSPIRO LODRANE 24 LOHIST 12HR VAZOL BROMPHENIRAMINE TANNATE BROMPHENIRAMINE TANNATE J-TAN P-TEX BROMPHENIRAMINE/DIPHENHYDRAM ALA-HIST CARBINOXAMINE MALEATE CARBINOXAMINE MALEATE PALGIC CHLORPHENIRAMINE MALEATE CHLORPHENIRAMINE MALEATE CPM 12 CHLORPHENIRAMINE TANNATE ED CHLORPED ED-CHLOR-TAN MYCI CHLOR-TAN MYCI CHLORPED PEDIAPHYL TANAHIST-PD CLEMASTINE FUMARATE CLEMASTINE FUMARATE CYPROHEPTADINE HCL CYPROHEPTADINE HCL DEXCHLORPHENIRAMINE MALEATE DEXCHLORPHENIRAMINE MALEATE DIPHENHYDRAMINE HCL ALLERGY MEDICINE ALLERGY RELIEF BANOPHEN BENADRYL BENADRYL ALLERGY CHILDREN'S ALLERGY CHILDREN'S COLD & ALLERGY COMPLETE ALLERGY DIPHEDRYL DIPHENDRYL DIPHENHIST DIPHENHYDRAMINE HCL DYTUSS GENAHIST HYDRAMINE MEDI-PHEDRYL PHARBEDRYL Q-DRYL QUENALIN SILADRYL SILPHEN DIPHENHYDRAMINE TANNATE DIPHENMAX DOXYLAMINE SUCCINATE
    [Show full text]
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • Brompheniramine Maleate, Pseudoephedrine Hydrochloride
    BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE, AND DEXTROMETHORPHAN HYDROBROMIDE- brompheniramine maleate, pseudoephedrine hydrochloride, and dextromethorphan hydrobromide syrup Morton Grove Pharmaceuticals, Inc. ---------- Brompheniramine Maleate, Pseudoephedrine Hydrochloride, and Dextromethorphan Hydrobromide Oral Syrup 2 mg/30 mg/10 mg per 5 mL Rx only DESCRIPTION Brompheniramine Maleate, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide Oral Syrup is a clear, light pink syrup with a butterscotch flavor. Each 5 mL (1 teaspoonful) contains: Brompheniramine Maleate, USP 2 mg Pseudoephedrine Hydrochloride, USP 30 mg Dextromethorphan Hydrobromide, USP 10 mg Alcohol 0.95% v/v In a palatable, aromatic vehicle. Inactive Ingredients: artificial butterscotch flavor, citric acid anhydrous, dehydrated alcohol, FD&C Red No. 40, glycerin, liquid sugar, methylparaben, propylene glycol, purified water and sodium benzoate. It may contain 10% citric acid solution or 10% sodium citrate solution for pH adjustment. The pH range is between 3.0 and 6.0. C16H19BrN2·C4H4O4 M.W. 435.31 Brompheniramine Maleate, USP (±)-2-p-Bromo-α-2-(dimethylamino)ethylbenzylpyridine maleate (1:1) C10H15NO · HCl M.W. 201.69 Pseudoephedrine Hydrochloride, USP (+)-Pseudoephedrine hydrochloride C18H25NO · HBr · H2O M.W. 370.32 Dextromethorphan Hydrobromide, USP 3-Methoxy-17-methyl-9α, 13α, 14α -morphinan hydrobromide monohydrate Antihistamine/Nasal Decongestant/Antitussive syrup for oral administration. CLINICAL PHARMACOLOGY Brompheniramine maleate is a
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • The Effect of Bromepheniramine on Cough Sensitivity in Normal Volunteers
    THE EFFECT OF BROMPHENIRAMINE ON COUGH SENSITIVITY IN HEALTHY VOLUNTEERS Haytham M. El-Khushman MD* ABSTRACT Objective: To evaluate the anti-tussive effect of brompheniramine maleate a non-selective, sedative antihistamine using capsaicin challenge. Methods: Twelve subjects, five females and seven females, mean age 32 years with a range of (23-39) years, were studied on two occasions. On the two visits a baseline capsaicin dose-response was performed to determine C5 (the lowest concentration causing 5 coughs). After 30 minutes two C5 doses of capsaicin were given and the total cough over one minute was counted. On the first visit Brompheniramine 8mg or a matched placebo was given orally, and 120, 240 minutes after administration, two C5 doses of capsaicin were given and the total coughs over one minute period were counted. This was repeated exactly in the second visit except subjects received either a placebo or active treatment; either which they had not received on their first visit. Subjects were also asked to quantify their drowsiness using a 100 mm visual analogue scale. Results: Baseline mean cough number (confidence interval) was similar on the two study occasions 9.9 (8.2-11.7) before Brompheniramine and 9.2 (7.3-11.1) before placebo. Cough number did not differ on the two study days at 120 and 240 min after Brompheniramine treatment: 7.7 (5.5-9.8), 7.4 (5.1-9.6) compared to 8.7 (6.4-11.0), 8.3 (6.8- 9.8) after placebo. Mean visual analogue scale (confidence interval) after Brompheniramine was 31 (14-48) and 40 (21-60) compared to 7 (2-12) and 7 (2-12) after Placebo at 120 and 240 min respectively (p<0.008).
    [Show full text]
  • Antihistamine Therapy in Allergic Rhinitis
    CLINICAL REVIEW Antihistamine Therapy in Allergic Rhinitis Paul R. Tarnasky, MD, and Paul P. Van Arsdel, Jr, MD Seattle, Washington Allergic rhinitis is a common disorder that is associated with a high incidence of mor­ bidity and considerable costs. The symptoms of allergic rhinitis are primarily depen­ dent upon the tissue effects of histamine. Antihistamines are the mainstay of therapy for allergic rhinitis. Recently, a second generation of antihistamines has become available. These agents lack the adverse effect of sedation, which is commonly associated with older antihistamines. Current practice of antihistamine therapy in allergic rhinitis often involves random selection among the various agents. Based upon the available clinical trials, chlorpheniramine appears to be the most reasonable initial antihistaminic agent. A nonsedating antihis­ tamine should be used initially if a patient is involved in activities where drowsiness is dangerous. In this comprehensive review of allergic rhinitis and its treatment, the cur­ rent as well as future options in antihistamine pharmacotherapy are emphasized. J Fam Pract 1990; 30:71-80. llergic rhinitis is a common condition afflicting some­ defined by the period of exposure to those agents to which A where between 15 and 30 million people in the United a patient is sensitive. Allergens in seasonal allergic rhinitis States.1-3 The prevalence of disease among adolescents is consist of pollens from nonflowering plants such as trees, estimated to be 20% to 30%. Two thirds of the adult grasses, and weeds. These pollens generally create symp­ allergic rhinitis patients are under 30 years of age.4-6 Con­ toms in early spring, late spring through early summer, sequently, considerable costs are incurred in days lost and fall, respectively.
    [Show full text]
  • (LSD) Test Dip Card (Urine) • Specimen Collection Container % Agreement 98.8% 99
    frozen and stored below -20°C. Frozen specimens should be thawed and mixed before testing. GC/MS. The following results were tabulated: Method GC/MS MATERIALS Total Results Results Positive Negative Materials Provided LSD Rapid Positive 79 1 80 LSD • Test device • Desiccants • Package insert • Urine cups Test Dip card Negative 1 99 100 Materials Required But Not Provided Total Results 80 100 180 One Step Lysergic acid diethylamide (LSD) Test Dip card (Urine) • Specimen collection container % Agreement 98.8% 99. % 98.9% • Timer Package Insert DIRECTIONS FOR USE Analytical Sensitivity This Instruction Sheet is for testing of Lysergic acid diethylamide. Allow the test device, and urine specimen to come to room temperature [15-30°C (59-86°F)] prior to testing. A drug-free urine pool was spiked with LSD at the following concentrations: 0 ng/mL, -50%cutoff, -25%cutoff, cutoff, A rapid, one step test for the qualitative detection of Lysergic acid diethylamide and its metabolites in human urine. 1) Remove the test device from the foil pouch. +25%cutoff and +50%cutoff. The result demonstrates >99% accuracy at 50% above and 50% below the cut-off For forensic use only. 2) Remove the cap from the test device. Label the device with patient or control identifications. concentration. The data are summarized below: INTENDED USE 3) Immerse the absorbent tip into the urine sample for 10-15 seconds. Urine sample should not touch the plastic Lysergic acid diethylamide (LSD) Percent of Visual Result The One Step Lysergic acid diethylamide (LSD) Test Dip card (Urine) is a lateral flow chromatographic device.
    [Show full text]
  • Medicines Classification Committee
    Medicines Classification Committee Meeting date 1 May 2017 58th Meeting Title Reclassification of Sedating Antihistamines Medsafe Pharmacovigilance Submitted by Paper type For decision Team Proposal for The Medicines Adverse Reactions Committee (MARC) recommended that the reclassification to committee consider reclassifying sedating antihistamines to prescription prescription medicines when used in children under 6 years of age for the treatment of medicine for some nausea and vomiting and travel sickness [exact wording to be determined by indications the committee]. Reason for The purpose of this document is to provide the committee with an overview submission of the information provided to the MARC about safety concerns associated with sedating antihistamines and reasons for recommendations. Associated March 2013 Children and Sedating Antihistamines Prescriber Update articles February 2010 Cough and cold medicines clarification – antihistamines Medsafe website Safety information: Use of cough and cold medicines in children – new advice Medicines for Alimemazine Diphenhydramine consideration Brompheniramine Doxylamine Chlorpheniramine Meclozine Cyclizine Promethazine Dexchlorpheniramine New Zealand Some oral sedating antihistamines available without exposure to a prescription (pharmacist-only and pharmacy only), sedating therefore usage data is not easily available. antihistamines Table of Contents 1.0 PURPOSE ......................................................................................................................................
    [Show full text]
  • Azelastine Hydrochloride
    568 Antihistamines been withdrawn from the market in most countries because of the Preparations treatment of non-allergic rhinitis in adults and children risk of adverse effects. USP 31: Azatadine Maleate Tablets. aged 12 years and over. The dose is 2 sprays into each Astemizole has been given in an oral dose of 10 mg once daily, Proprietary Preparations (details are given in Part 3) nostril twice daily. In the treatment of conjunctivitis, or 5 mg daily in children aged 6 to 12 years. These doses must Austral.: Zadine; Canad.: Optimine; Hong Kong: Zadine†; Malaysia: azelastine is licensed in the UK for the treatment of not be exceeded because of the risk of cardiac arrhythmias with Zadine†; Mex.: Idulamine†; NZ: Zadine†; Singapore: Zadine†; Spain: seasonal allergic conjunctivitis in adults and children higher doses. Lergocil. aged 4 years and over and for the treatment of perenni- The active metabolite of astemizole, tecastemizole (norastemi- Multi-ingredient: Braz.: Cedrin; Canad.: Trinalin; Mex.: Trinalin†; al allergic conjunctivitis in adults and children aged 12 zole) has been investigated for the treatment of allergic rhinitis. Spain: Atiramin; Idulanex; USA: Rynatan†; Trinalin†. years and over. In the USA, it is licensed for the treat- Preparations ment of allergic conjunctivitis in adults and children USP 31: Astemizole Tablets. aged 3 years and over. Regardless of the age and indi- Azelastine Hydrochloride cation, a 0.05% solution is instilled into each eye twice Proprietary Preparations (details are given in Part 3) (BANM, USAN, rINNM) daily; this may be increased to four times daily in se- Arg.: Alermizol†; Astezol†; Cezane†; Mudantil†; Cz.: Hismanal†; Gr.: Mibiron†; Tulipe-R†; Tyrenol†; Waruzol†; India: Astizole; Stemiz†; Mex.: A-5610 (azelastine or azelastine hydrochloride); Atselastiinihy- vere conditions.
    [Show full text]
  • Evaluation of the ACQUITY UPLC H-Class System With
    [ TECHNOLOGY BRIEF ] Evaluation of the ACQUITY UPLC H-Class System with ACQUITY QDa Mass Detector for the Determination of Amphetamine, Methamphetamine, Ketamine, and Norketamine in Human Urine for Forensic Toxicology Nayan S. Mistry, Rob Lee, and Michelle Wood Waters Corporation, Wilmslow, UK The ACQUITY QDa Mass Detector has demonstrated great promise as an alternative technique to immunoassay. GOAL To assess the feasibility of using the Waters™ ACQUITY™ UPLC™ H-Class System with the ACQUITY QDa™ Mass Detector (Figure 1) as an alternate technique to immunoassay for illicit drug analysis and quantification. BACKGROUND Amphetamines (methamphetamine and amphetamine) are among the most commonly abused illicit substances in the world. In 2016, it was estimated that around 35 million adults worldwide used amphetamines.¹ The region with the highest annual use was North America at Figure 1. The ACQUITY UPLC H-Class System and ACQUITY QDa Mass Detector. approximately 2% of the population. In the last few years however, there also appears Forensic laboratories often utilize immunoassay for routine urine analysis. to be a marked increase in consumption While the technique is rapid and simple, there can be some disadvantages, within other geographies, particularly often associated with poor selectivity for example, false positive results for East and Southeast Asia, where the amphetamine or ketamine have been reported for a variety of substances.3-5 amphetamines have been identified as As most positive immunoassay results require a confirmatory test (such as one of the most worrying threats of drug GC or LC-MS), the consequence of false positive identifications, as a result use. Moreover, a rise in the use of Ecstasy of poor assay selectivity, can significantly compromise laboratory efficiency.
    [Show full text]
  • UQ272429 OA.Pdf
    Cochrane Database of Systematic Reviews Oral antihistamine-decongestant-analgesic combinations for the common cold (Review) De Sutter AIM, van Driel ML, Kumar AA, Lesslar O, Skrt A De Sutter AIM, van Driel ML, Kumar AA, Lesslar O, Skrt A. Oral antihistamine-decongestant-analgesic combinations for the common cold. Cochrane Database of Systematic Reviews 2012, Issue 2. Art. No.: CD004976. DOI: 10.1002/14651858.CD004976.pub3. www.cochranelibrary.com Oral antihistamine-decongestant-analgesic combinations for the common cold (Review) Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 BACKGROUND .................................... 3 OBJECTIVES ..................................... 3 METHODS ...................................... 4 RESULTS....................................... 5 Figure1. ..................................... 7 Figure2. ..................................... 8 DISCUSSION ..................................... 19 AUTHORS’CONCLUSIONS . 20 ACKNOWLEDGEMENTS . 20 REFERENCES ..................................... 21 CHARACTERISTICSOFSTUDIES . 24 DATAANDANALYSES. 64 Analysis 1.1. Comparison 1 Combination 1: Antihistamine-decongestant, Outcome 1 Global evaluation. 66 Analysis 1.2. Comparison 1 Combination 1: Antihistamine-decongestant, Outcome 2 Side effects: all - Combination 1: Antihistamine-decongestant. 67 Analysis 1.3. Comparison 1 Combination 1: Antihistamine-decongestant,
    [Show full text]